CJ Bioscience, Inc. (KOSDAQ: 311690)

Market Cap	92.22B
Revenue (ttm)	3.97B
Net Income (ttm)	-21.62B
Shares Out	9.11M
EPS (ttm)	-2,370.64
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	100,878
Open	10,160
Previous Close	10,120
Day's Range	10,010 - 10,670
52-Week Range	8,250 - 18,800
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Mar 20, 2025

About CJ Bioscience

CJ Bioscience, Inc. provides microbiome solutions to address unmet medical needs in South Korea and internationally. The company’s platform is Ez-Mx, a bioinformatics-based platform for microbiome data analysis. Its product pipeline includes CJRB-101 that is phase I clinical trial for solid tumors; CJRB-201, CJRB-202, and CJRB-203 for inflammatory bowel diseases; CJRB-302 for Parkinson’s diseases; CJRB-401 and CJRB-402 for asthma. The company also provides next-generation sequencing analysis services; EzBioCloud, a database and bioinformatics a...

• Industry: Computer Programming, Data Processing, And Other Computer Related Services
• Founded: 2009
• Country: South Korea
• Stock Exchange: KOSDAQ
• Ticker Symbol: 311690

Financial Performance

In 2023, CJ Bioscience's revenue was 5.58 billion, an increase of 36.82% compared to the previous year's 4.07 billion. Losses were -22.91 billion, -34.37% less than in 2022.